| 1 |
Hashemi M, Rashidi M, Hushmandi K, Ten Hagen TLM, Salimimoghadam S, Taheriazam A, Entezari M, Falahati M. HMGA2 regulation by miRNAs in cancer: affecting cancer hallmarks and therapy response. Pharmacol Res 2023;:106732. [PMID: 36931542 DOI: 10.1016/j.phrs.2023.106732] [Reference Citation Analysis]
|
| 2 |
Huang C, Qin L, Chen S, Huang Q. CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression. Anticancer Drugs 2023;34:395-404. [PMID: 36729852 DOI: 10.1097/CAD.0000000000001465] [Reference Citation Analysis]
|
| 3 |
Gaudreau-Lapierre A, Klonisch T, Nicolas H, Thanasupawat T, Trinkle-Mulcahy L, Hombach-Klonisch S. Nuclear High Mobility Group A2 (HMGA2) Interactome Revealed by Biotin Proximity Labeling. Int J Mol Sci 2023;24. [PMID: 36835656 DOI: 10.3390/ijms24044246] [Reference Citation Analysis]
|
| 4 |
Wang H, Liu S, Sha X, Gao X, Liu G, Jiang X. Unveiling the prominent roles of circular RNAs ubiquitin binding associated protein 2 in cancers. Pathol Res Pract 2023;241:154282. [PMID: 36580797 DOI: 10.1016/j.prp.2022.154282] [Reference Citation Analysis]
|
| 5 |
Linghui HU, Wei WU, Jun ZOU. Circular RNAs: typical biomarkers for bone-related diseases. J Zhejiang Univ Sci B 2022;23. [PMID: 36518051 DOI: 10.1631/jzus.B2200211] [Reference Citation Analysis]
|
| 6 |
Xia Y, Wang D, Piao Y, Chen M, Wang D, Jiang Z, Liu B. Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1025532] [Reference Citation Analysis]
|
| 7 |
Fan L, Zhong Z, Lin Y, Li J. Non-coding RNAs as potential biomarkers in osteosarcoma. Front Genet 2022;13:1028477. [DOI: 10.3389/fgene.2022.1028477] [Reference Citation Analysis]
|
| 8 |
Weidle UH, Sela T, Brinkmann U, Niewoehner J. Circular RNAs With Efficacy in Preclinical In Vitro and In Vivo Models of Esophageal Squamous Cell Carcinoma. Cancer Genomics Proteomics 2022;19:283-98. [PMID: 35430563 DOI: 10.21873/cgp.20320] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Wang L, Yang X, Zhou F, Sun X, Li S. Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis. Bioengineered 2022;13:7197-208. [PMID: 35263216 DOI: 10.1080/21655979.2022.2036894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Ma W, Zhao X, Gao Y, Yao X, Zhang J, Xu Q. Circular RNA circ_UBAP2 facilitates the progression of osteosarcoma by regulating microRNA miR-637/high-mobility group box (HMGB) 2 axis. Bioengineered 2022;13:4411-27. [PMID: 35114890 DOI: 10.1080/21655979.2022.2033447] [Reference Citation Analysis]
|
| 11 |
Huang W, Wu Y, Qiao M, Xie Z, Cen X, Huang X, Zhao Z. CircRNA-miRNA networks in regulating bone disease. J Cell Physiol 2021. [PMID: 34796958 DOI: 10.1002/jcp.30625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 12 |
Lakiotaki E, Kanakoglou DS, Pampalou A, Karatrasoglou EA, Piperi C, Korkolopoulou P. Dissecting the Role of Circular RNAs in Sarcomas with Emphasis on Osteosarcomas. Biomedicines 2021;9:1642. [PMID: 34829872 DOI: 10.3390/biomedicines9111642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Ma S, Gu X, Shen L, Chen Y, Qian C, Shen X, Ju S. CircHAS2 promotes the proliferation, migration, and invasion of gastric cancer cells by regulating PPM1E mediated by hsa-miR-944. Cell Death Dis 2021;12:863. [PMID: 34556632 DOI: 10.1038/s41419-021-04158-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Zhang Y, Chang J, Jiang W, Ye X, Zhang S. Long non-coding RNA CASC9/microRNA-590-3p axis participates in lutein-mediated suppression of breast cancer cell proliferation. Oncol Lett 2021;22:544. [PMID: 34084220 DOI: 10.3892/ol.2021.12805] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
